Ocular Therapeutix Inc (NAS:OCUL)
$ 5.8 -0.2 (-3.33%) Market Cap: 898.36 Mil Enterprise Value: 520.85 Mil PE Ratio: 0 PB Ratio: 2.20 GF Score: 78/100

Ocular Therapeutix Inc Research & Development Day Transcript

Mar 28, 2019 / 11:30AM GMT
Release Date Price: $3.98 (-1.00%)
Antony Mattessich
Ocular Therapeutix, Inc. - President, CEO & Director

All right. Well, welcome, everyone, and welcome, everyone, on the webcast to the pipeline review for Ocular Therapeutix. It is a -- it's been a long, long winding road to get to where we are today, which is actually a very, very exciting moment in the company. We're about to launch our first product, our first pharma product, but we also have a tremendous pipeline behind that and a tremendous amount of opportunities that our platform brings us. So if you leave today with 2 thoughts, what I really hope that you'll think is, first of all, there's a lot of opportunity in this company, but the second is that they are focused on what they need to do. And we have the focus because we, like everyone else, are looking at the capital markets and the equity markets the way they are and realizing that the days of endless cash flow are probably over and that we need to be able to really generate our own cash flow in the very near term to be able to ensure that we're able to access the kind of capital we need in order to feed the pipeline we

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot